Market Research Life Sciences Market Research Diagnostics Market Research In Vitro Diagnostics Market Research Molecular Diagnostics Market Research

Kalorama Information 2017 Regional IVD Market Bundle

Best Price Guarantee Length Publisher Published Date SKU
from $7,995 845 Pages Kalorama Information September, 2017 KLI15481266
Best Price Guarantee
Price from $7,995
Length 845 Pages
Publisher Kalorama Information
Published Date September, 2017
SKU KLI15481266

This report contains five separate market research studies that combine for 840 pages of market information about emerging IVD markets, including: Kalorama Information has:

  • United States IVD Market (2016)
  • Brazil IVD Markets (2017)
  • Indonesia IVD Markets (2017
  • Mexico IVD Markets (2017)
  • India IVD Market (2016)
This Kalorama Information Bundle is designed to provide cost savings to market researchers by providing several of our popular reports in one package.  This report, consisting of a combined PDF with five reports, each with their own TOC provides regional IVD markets, company profiles and more.


----------------------UNITED STATES IVD MARKET


1: Executive Summary
Introduction
Market Metrics – Utilization
Market Metrics – Aging
Market Metrics – Disease
Market Metrics – U.S. Total Health and Clinical Lab Expenditures and Payers
Market Metrics – U.S. Clinical Testing by Channel
Impacts of the Affordable Care Act
Impacts of PAMA and LDT Reform
U.S. IVD Market
Top Tier U.S. IVD Market Participants and Rankings
Conclusions
2: Introduction to U.S. Health Care
The United States and In Vitro Diagnostics
U.S. Patient Population
Healthcare System Utilization
Aging
Disease Prevalence and Incidence
Health Insurance in the United States and the Affordable Care Act
U.S. Health Expenditure
U.S. Clinical Lab Expenditure
Affordable Care Act (ACA)
Clinical Testing under Medicare – Reimbursement Cuts and Market-Based Pricing 55
Protecting Access to Medicare Act of 2014 (PAMA)
Molecular Diagnostics and Medicare Policy
Laboratory-Developed Tests (LDTs) Invigorate Market, Challenge Regulators
U.S. Healthcare Infrastructure and Testing Channels
Hospitals
Independent Labs
Physician Office Laboratories
Self-Testing
Retail Clinics
Conclusions
3: U.S. IVD Market Analysis
Clinical Chemistry
Microbiology and Virology – ID/AST and Molecular
Point-of-Care Testing
Immunoassays
Urinalysis
Molecular Diagnostics
Coagulation
Histology
Hematology
Blood Testing and Typing
Flow Cytometry
Total U.S. IVD Market
4: Top Tier U.S. IVD Market Players
Abbott Diagnostics
Core Lab
Hematology
Molecular
Blood Testing
Mass Spectrometry ID/AST
Diabetes Testing
Point-of-Care (POC) Diagnostics
Alere
Critical Care
Lipids and Cardiac Markers
Diabetes Testing
Coagulation
Toxicology / Drugs of Abuse
Infectious Diseases
Beckman Coulter (Danaher)
Immunoassays
Clinical Chemistry
Hematology
Microbiology
Urinalysis
Flow Cytometry
Molecular
Becton, Dickinson and Company (BD)
Microbiology
Mass Spectrometry
Immunoassays
Molecular
Histology/Cytology
Flow Cytometry
bioMérieux
Microbiology
Mass Spectrometry
Immunoassays
Molecular
Sequencing
Bio-Rad Laboratories
Microbiology
Hemoglobinopathy and Diabetes Testing
Immunoassays
Blood Typing and Testing
Tissue Typing
Sequencing
Cepheid
Molecular Hospital-Acquired Infection (HAI) Testing
Molecular Sexual Health and Women’s Health Testing
Molecular Critical Infectious Disease Testing
Molecular Oncology Testing
Danaher Corporation
Histology
Point-of-Care Testing
Hologic
Molecular Cytology / Histology (HPV)
Other Molecular (STIs, HIV, HCV, TB, Respiratory)
Microbiology (AccuProbe Molecular Culture ID Tests)
Blood Testing (Molecular PROCLEIX Tests)
Johnson & Johnson (Incl. Janssen Diagnostics)
Ortho-Clinical Diagnostics
Core Lab
Blood Testing and Typing
QIAGEN
Molecular Infectious Disease
Companion Diagnostics
Immunoassays
Next-Generation Sequencing
Roche Diagnostics
Professional Diagnostics
Immunoassays
Point-of-Care Diagnostics
Diabetes Care
Tissue Diagnostics
Molecular Diagnostics
Blood Testing
Sequencing
Microbiology (GeneWeave)
Siemens Healthcare Diagnostics
Clinical Chemistry
Immunoassays
Hematology
Molecular Diagnostics and Histology
Urinalysis
Coagulation
Point-of-Care Diagnostics
Sysmex Corporation
Hematology
Coagulation
Urinalysis
Thermo Fisher Scientific
Immunoassays
Drug Testing
Histology
Mass Spectrometry
Microbiology
Molecular
Sequencing

L I S T   O F   E X H I B I T S

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: U.S. Commercially Insured Members’ Encounters with Ambulatory Physicians (per 1,000 Members) (2005-2014)

  • Table 1-2: Historical and Projected U.S. Aged Populations (60+) (% Share of Total Population, Population in Millions) (1950-2050)

  • Table 1-3: U.S. IVD Market by Segment (2015/2020)

  • Table 1-4: U.S. IVD Market Rankings by Estimated 2015 Revenue – Top 15 Companies

    • CHAPTER TWO: INTRODUCTION

  • Figure 2-1: U.S. IVD Market (2015/2020)

  • Table 2-1: U.S. Hospital Inpatient Admissions and Outpatient Visits Per 1,000 Persons (1994-2013)

  • Table 2-2: U.S. Commercially Insured Members’ Encounters with Ambulatory Physicians (per 1,000 Members) (2005-2014)

  • Table 2-3: Historical and Projected U.S. Aged Populations (60+) (% Share of Total Population, Population in Millions) (1950-2050)

  • Table 2-4: U.S. Cancer Incidence – Aggregate, Lung, Colon, Prostate, Breast (per 100,000 persons) (2002-2012)

  • Table 2-5: Selected Notifiable Infectious Disease Incidences in the United States (per 100,000 persons) (2003-2013)

  • Table 2-6: U.S. National Health Expenditure by Payer (Out-of-Pocket, Private Health Insurance, Medicare, Medicaid) (2013-2020)

  • Table 2-7: U.S. Clinical Laboratory Market by Segment - Hospital, Independent, Physician Office (2013-2020)

  • Figure 3-1: U.S. Clinical Chemistry Market (2015/2020)

  • Figure 3-2: U.S. ID/AST Microbiology Market (2015/2020)

  • Figure 3-3: U.S. Molecular Microbiology / Virology Market (2015/2020)

    • CHAPTER THREE: MARKET ANALYSIS

  • Table 3-1: U.S. ID/AST Microbiology Market – Automated ID/AST, Manual/Semi-Auto ID/AST, Blood Culture, Chromogenic Media, Rapid Micro (2015/2020)

  • Table 3-2: U.S. Molecular Microbiology / Virology Market – HAIs/BSIs, HIV, Hepatitis, CT/NG, HPV, Respiratory, Mycobacteria/TB, Other (2015/2020)

  • Figure 3-4: U.S. Point-of-Care (POC) Diagnostics Markets – Professional, OTC Diabetes, OTC Other (2015/2020)

  • Table 3-3: U.S. Point-of-Care (POC) Diagnostics Markets – Professional (Drugs of Abuse, Infectious Disease, Pregnancy, Glucose, HbA1c, Lipids, Cardiac Markers, FOB, Critical Care, Coagulation, Hematology, Other), OTC Diabetes, OTC Other (2015/2020)

  • Figure 3-5: U.S. Immunoassays Markets – Infectious and Non-Infectious (2015/2020)

  • Table 3-4a: U.S. Immunoassays Market – Non Infectious (Cardiac Markers, Tumor Markers, HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs, Drugs of Abuse, Vitamin D) (2015/2020)

  • Table 3-4b: U.S. Immunoassays Market – Infectious (Hepatitis, HIV, STDs, ToRCH, Respiratory, HAIs/Sepsis, Parasitology, Mycology, Others)

  • Figure 3-6: U.S. Urinalysis Lab Diagnostics Market (2015/2020)

  • Figure 3-7: U.S. Molecular Diagnostics Market (2015/2020)

  • Figure 3-8: U.S. Coagulation Diagnostics Market (2015/2020)

  • Figure 3-9: U.S. Histology and Cytology Diagnostics Market (2015/2020)

  • Figure 3-10: U.S. Hematology Diagnostics Market (2015/2020)

  • Figure 3-11: U.S. Blood Testing and Typing Diagnostics Market (2015/2020)

  • Figure 3-12: U.S. Clinical Flow Cytometry Market (2015/2020)

  • Table 3-5: U.S. IVD Market by Segment (2015/2020)

    • CHAPTER FOUR: COMPANY PROFILES

  • Table 4-1: Abbott Diagnostics Revenue (2012-2015)

  • Table 4-2: Alere Revenue (2012-2015)

  • Table 4-3: Beckman Coulter Revenue (2012-2015)

  • Table 4-4: BD Revenue (FY 2012-FY 2015)

  • Table 4-5: bioMérieux Revenue (2012-2015)

  • Table 4-6: Bio-Rad Laboratories Revenue (2012-2015)

  • Table 4-7: Cepheid Revenue (2012-2015)

  • Table 4-8: Danaher Diagnostics Group Subsidiary Revenue (Beckman Coulter, Radiometer, Leica Biosystems) (2012-2015)

  • Table 4-9: Hologic Revenue (FY 2012-FY 2015)

  • Table 4-10: Johnson & Johnson Diagnostics Revenue (2012-2015)

  • Table 4-11: QIAGEN Revenue (2012-2015)

  • Table 4-12: Roche Diagnostics Revenue (2012-2015)

  • Table 4-13: Siemens Healthcare Diagnostics Revenue (FY 2012-FY 2015)

  • Table 4-14: Sysmex Corporation Revenue (FY 2012-FY 2015)

  • Table 4-15: Thermo Fisher Scientific Revenue (2012-2015)


    ---------------------------------BRAZIL MARKET ANALYSIS

    CHAPTER 1: EXECUTIVE SUMMARY
    INDUSTRY OVERVIEW
    SCOPE AND METHODOLOGY
    BRAZIL IVD MARKET SUMMARY
    Figure 1-1: Brazil In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other)
    CHAPTER 2: BRAZIL OVERVIEW
    POPULATION
    Table 2-1: Total Midyear Population by Broad Age Group: Brazil (million persons), 2010-2050 (0-14, 15-64, 65+)
    Figure 2-1: Total Midyear Population by Broad Age Group: Brazil (million persons), 2010-2050 (0-14, 15-64, 65+)
    Figure 2-2: Total Number of Births in Brazil by Year, 1970-2010, and Forecast 2020-2050
    Figure 2-3: Brazil Life Expectancy at Birth in Years, 2010-2050
    Population Urbanization
    ECONOMY AND HEALTH SPENDING
    Figure 2-4: Brazil GDP, GDP (PPP) and Health Spending, 1990-2015
    Figure 2-5: Brazil Distribution of Income or Consumption by Quintile, 1990-2014
    CHAPTER 3: THE HEALTH SYSTEM IN BRAZIL
    HEALTH INFRASTRUCTURE
    Figure 3-1: Brazilian Coverage Rate (%) for Private Health Plans and Public Health Plans, 2003-2015 (Private Medical Aid Plan Beneficiaries with or without Dental Care, Public Health Plan Beneficiaries)
    Figure 3-2: Health Expenditures, Public vs. Private as a % of Total Health Expenditures, 2015 (Private, Public)
    Medical Facilities
    Figure 3-3: Distribution of JCI Accredited Facilities by Metropolitan Area (%) (Sao Paulo, Rio de Janeiro, Recife, Brasilia, Porto Alegre, Others)
    Figure 3-4: Distribution of JCI Accredited Facilities by Type (%) (Hospital Program, Academic Medical Center, Ambulatory Care, Home Care, Medical Transport, Primary Care)
    Figure 3-5: Hospital Bed Density per 1,000 Population by Country, 2016 Estimates (US, UK, Singapore, Japan, Germany, China, Canada, Brazil, Australia)
    Physicians and Health Professionals
    Figure 3-6: Physician Density per 1,000 Population by Country, 2016 Estimates (US, UK, Singapore, Japan, Germany, China, Canada, Brazil, Australia)
    Figure 3-7: Nurse/Midwife Density per 1,000 Population by Country, 2016 Estimates (US, UK, Singapore, Japan, Germany, China, Canada, Brazil, Australia)
    The Brazilian Diagnostic Laboratory Environment
    Figure 3-8: Laboratories and Collection Sites in Brazil by Type (%), 2016 (Collection Sites, all types; Commercial Laboratories; Hospital-based Laboratories)
    Figure 3-9: Distribution of Volume, Brazil's Leading Clinical Laboratory Service Providers (%), 2016
    Medical Device Regulation
    Table 3-1: Market Divers and Inhibitors for Entering Brazil's Medical Device Market
    Figure 3-10: Market Entry Complexity for Foreign Operators in Brazil
    Brazil's Growing Medical Tourism Industry
    HEALTH INDICATORS
    General Health
    Disease Profiles in Brazil
    Table 3-2: Top 5 Cancers Affecting Brazilian Population (ranked by total number of cases), 2010-2016 (Male, Female, Total [both sexes])
    Figure 3-11: Highly Prevalent Medical Conditions/Diseases in Brazil (Zika virus, Tuberculosis, Malaria, Leprosy, HIV, Diabetes, Dengue, Chagas disease, Cardiovascular diseases, Cancer)
    Surgical Procedures in Brazil
    Table 3-3: Surgical Procedures in Brazil as Compared to Rest of Latin America (%) (Cardiovascular procedures, Digestive/Gastrointestinal procedures, Obstetrical/Gynecological procedures, Orthopedic procedures, ENT/Respiratory procedures, Urinary surgical procedures, Cosmetic/Aesthetic procedures, Other procedures, Total)
    Figure 3-12: Brazil, Mexico and Rest of LATAM Distribution of Population Compared to Surgical Procedures (%)
    CHAPTER 4: IVD MARKETS IN BRAZIL
    BRAZIL IVD MARKET SUMMARY
    Table 4-1: Brazil In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry, Immunoassay, Microbiology/Molecular, POC, Histology, Other, Total)
    Figure 4-1: Brazil In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other)
    Figure 4-2: Brazil In Vitro Diagnostic Sales by Market Segment, 2016 Market Distribution (%) (Clinical Chemistry, Immunoassays, Microbiology/Molecular, POC, Histology, Other)
    CLINICAL CHEMISTRY
    Figure 4-3: Brazil - Clinical Chemistry Market, 2016-2021
    IMMUNOASSAY
    Table 4-2: Brazil - Immunoassay Market Distribution, 2016-2021 (%) (Infectious Disease, Other, Total Immunoassay)
    Figure 4-4: Brazil - Immunoassay Market Value by Segment, 2016 vs. 2021 (Infectious Disease, Other)
    MICROBIOLOGY/MOLECULAR
    Table 4-3: Brazil - Microbiology/Molecular Testing Market Distribution, 2016-2021 (%) (Infectious Disease, Other, Total Microbiology/Molecular Testing)
    Figure 4-5: Brazil Microbiology/Molecular Testing Market Value by Segment, 2016 vs. 2021 (Infectious Disease, Other)
    POINT-OF-CARE
    Table 4-4: Brazil - POC Market Distribution, 2016-2021 (%) (POC Glucose, POC Infectious Disease, POC Other, Total POC)
    Figure 4-6: Brazil POC Market Value by Segment, 2016 vs. 2021 (POC Glucose, POC Infectious Disease, Others)
    HISTOLOGY
    Figure 4-7: Brazil - Histology Market, 2016-2021
    CHAPTER 5: COMPETITIVE ANALYSIS AND PROFILES
    COMPETITIVE SUMMARY
    Table 5-1: Leading IVD Market Suppliers in Brazil, Market Share Percentage, 2016
    Figure 5-1: Leading IVD Market Suppliers in Brazil, 2016 (%)
    ABBOTT LABORATORIES
    Table 5-2: Abbott Laboratories Company Summary
    Company Overview
    Company Performance
    Product Summary
    ALERE
    Table 5-3: Alere Company Summary
    Company Overview
    Performance Review
    Product Summary
    BECTON, DICKINSON AND COMPANY
    Table 5-4: Becton, Dickinson and Company Summary
    Company Overview
    Company Performance
    Product Summary
    BIOMÉRIEUX SA
    Table 5-5: bioMerieux Summary
    Company Overview
    Company Performance
    Product Summary
    DANAHER CORPORATION
    Table 5-6: Danaher Corporation Summary
    Company Overview
    Company Performance
    Product Summary
    ROCHE (F. HOFFMAN-LA ROCHE, LTD.)
    Table 5-7: Roche Group Summary
    Company Overview
    Company Performance
    Product Summary
    SIEMENS HEALTHINEERS
    Table 5-8: Siemens Healthineers Company Summary
    Company Overview
    Company Performance
    Product Summary
    SYSMEX CORPORATION
    Table 5-9: Sysmex Corporation Summary
    Company Overview
    Company Performance
    Product Summary
     

    ---------------------------------INDONESIA MARKET ANALYSIS


    CHAPTER ONE: EXECUTIVE SUMMARY

    INTRODUCTION
    Figure 1-1: Map of Indonesia, with Provinces

    Figure 1-2: Total Population of Indonesia (2000-2016)

    Table 1-1: GDP Growth in Indonesia, 2012-2015
    HEALTH STATUS OF INDONESIANS

    HEALTHCARE DELIVERY SYSTEM

    REGULATION OF IVD DEVICES AND DISTRIBUTION

    SCOPE AND METHODOLOGY

    SIZE AND GROWTH OF THE IVD MARKET

    Figure 1-3: IVD Market in Indonesia, 2017 and 2022
    CHAPTER TWO: INDONESIA - A GROWING IVD MARKET

    HEALTHCARE EXPENDITURE IN INDONESIA
    Figure 2-1: Growth of Health Expenditure per Capita (USD) in Indonesia, 2000-2014

    Figure 2-2: Growth of Health Expenditure per Capita in PPP Terms (USD), Indonesia, 2000-2014
    HEALTH INDICATORS IN INDONESIA
    Figure 2-3: Top 10 Causes of Death in Indonesia

    Table 2-1: Life Expectancy and Mortality Rates in Indonesia, 2000-2014 (Life Expectancy, Total; Life Expectancy at Birth, Male; Life Expectancy at Birth, Female; Total Mortality Rate, Adult, Male; Total Mortality Rate, Adult, Female)
    PREVALENT INFECTIOUS DISEASES IN INDONESIA
    Tuberculosis (TB)

    Table 2-2: Assessment of TB Burden in Indonesia, WHO

    Table 2-3: Pulmonary Tuberculosis Cases by Province, Indonesia 

    HIV/AIDS

    Table 2-4: The Number of New Cases of HIV and AIDS between 2011 and 2015, Indonesia

    Table 2-5: HIV and AIDS Cases in Indonesia, by Province 

    Malaria

    Table 2-6: Incidence of Malaria in Indonesia, by Province 

    Dengue

    Table 2-7: Dengue Hemorrhagic Fever (DHF) Cases in Indonesia, by Province 

    Filariasis

    Table 2-8: Filariasis in Indonesia, 2011-2015

    Table 2-9: Filariasis Cases in Indonesia, by Province, 2012-2014 


    Leptospirosis

    Table 2-10: Leptospirosis Cases in Indonesia, by Province, 2011-2015 

    Typhoid

    Table 2-11: Typhoid Prevalence in Indonesia, by Province 

    Human Papilloma Virus (HPV)
    INDONESIAN HEALTHCARE INDUSTRY LANDSCAPE
    Figure 2-4: Healthcare Delivery in Indonesia

    Healthcare Delivery System

    Public Healthcare System: General and Specialty Hospitals

    Table 2-12: General and Specialty Hospitals in Indonesia, 2011-2015

    Public Healthcare System: Community Healthcare Centers (CHCs/Puskesmas)

    Table 2-13: Community Healthcare Centers in Indonesia, 2011-2015


    Table 2- 14: Distribution of Puskesmas (CHCs) in Indonesia across 34 Provinces

    Hospital Classification in Indonesia

    Table 2-15: Selected General and Specialty Hospitals in Indonesia

    Private Healthcare System

    Table 2-16: Selected Leading Private Hospitals in Indonesia, by Province


    Private Labs in Indonesia

    Table 2-17: Selected Private Laboratories in Indonesia

    FINANCIAL ASPECTS OF THE HEALTHCARE INDUSTRY IN INDONESIA

    Table 2-18: Indonesia Healthcare Spending Compared to Southeast Asia Neighbors (New Zealand, Japan, Australia, South Korea, 

    Vietnam, China, Singapore, India, Malaysia, Thailand)

    Table 2-19: Indonesia Healthcare Expenditure, 2000-2014 (Total Health Expenditure as % of GDP, Public Health Expenditure, Private 
    Health Expenditure)

    Implementation of UHC

    Private Health Insurance
    E-CATALOGUE PRICING SYSTEM

    KEY MARKET DRIVERS OF THE INDONESIAN HEALTHCARE MARKET

    KEY CHALLENGES IN THE INDONESIAN HEALTHCARE MARKET
    Uncertainty among Private Insurers

    Rigid Reference Model Hampering Healthcare Accessibility

    Limited Access to Quality Healthcare Facilities

    Gap between Supply and Demand of Medical Professionals

    Impact of the E-Catalogue Pricing System


    Impact of Government’s Policies on Foreign Direct Investments (FDI)

    Logistics Challenges
    IVD PRODUCT REGULATION IN INDONESIA
    Table 2-20: Classification of Medical Devices
    IMPORTANT FACTORS TO CONSIDER WHILE CHOOSING AN IVD DISTRIBUTOR IN INDONESIA
    Trade-Off between Small and Big Distributors
    Table 2-21: Selected Foreign Companies and Their Key Distributors in Indonesia
    PROCESSES FOR DISTRIBUTION LICENSE, COMPANY AND PRODUCT REGISTRATIONS
    Company/Product Registration
    Table 2-22: Licenses Required for IVD Distribution in Indonesia
    REGULATORY TRENDS AND INSIGHTS RELEVANT FOR THE IVD SECTOR
    Market Transition to E-Catalogue and Related Regulations
    REGULATIONS FOR FOREIGN DIRECT INVESTMENTS (FDI)
    Table 2-23: Indonesia Investment Coordinating Board (BKPM) Offices
    SETTING UP A COMPANY IN INDONESIA
    Table 2-24: Options for a Foreign IVD Company to Enter the Indonesian Market

    Assessing Option 1: Opening an Affiliated Branch Office in Indonesia

    Assessing Option 2: Select a Suitable Exclusive Distributor

    Assessing Option 3: Set up OEM Operations; Invest in Local Manufacturing within 3 years

    BUSINESS STRATEGIES ADOPTED BY MULTINATIONAL COMPANIES (MNCS): CASE STUDIES
    Roche

    bioMerieux

    Thermo Fisher Scientific

    Conclusion
    CHAPTER THREE: IVD MARKET ANALYSIS

    MICROBIOLOGY

    LFIA Tests (Rapid Tests) for Infectious Diseases
    Table 3-1: Sales of Rapid Tests for Infectious Diseases by Category, Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Rapid Tests-Infectious Diseases, Total)

    Table 3-2: Popular Rapid Test Brands and Their Distributors in Indonesia
    Lab-based Immunoassays for Infectious Diseases

    Table 3-3: STD Test Costs at Selected Clinics and Hospitals in Indonesia

    Table 3-4: Major Diseases and Demand for Lab-based Immunoassay Diagnostics in Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Lab-based Immunoassays - Infectious Diseases, Total)
    ID/AST
    Molecular Diagnostics

    Table 3-5: Microbiology Sales in Indonesia, 2017-2022 (Rapid Tests-Infectious Diseases; Lab-based Immunoassays - Infectious Diseases; Molecular Diagnostics - Microbiology; Other [includes supplies, reagents, etc.]; Microbiology, Total)
    HEMATOLOGY
    Table 3-6: List of Major Players in the Indonesian Hematology Market

    Table 3-7: Hematology Sales by Category, Indonesia, 2017-2022 (Hematology Systems; Hematology POC; Other [Digital imaging, analysis software, etc.]; Hematology, Total)
    CLINICAL CHEMISTRY
    Table 3-8: List of Major Players in the Indonesian Clinical Chemistry Market

    Table 3-9: Clinical Chemistry Analyzer Sales by Category, Indonesia, 2017-2022 (General Chemistry; Blood Gas Analyzers; Critical Care POC; Clinical Chemistry, Total)

    POINT-OF-CARE TESTS

    POC - OTC/ Self-Testing

    POC – Professional-Testing

    POC Hand-Held Devices

    POC Bench-Top Analyzers

    Table 3-10: POC Sales by Category, Indonesia, 2017-2022 (POC-Diabetes; POC-OTC/Self-Testing, Other; POC-OTC/Self Testing, Total; 
    Cardiac Markers; DOA/Toxicology; Other; POC-Professional, Total; POC, Total)

    IMMUNOASSAYS

    Point-of-Care (POC) Immunoassays

    Immunoassays for Non-Infectious Diseases

    Table 3-11: Immunoassay (Non-Infectious) Sales by Category, Indonesia, 2017-2022 (Diabetes; Cardiac markers; Other [Cancer 
    Markers, DOA tests; cholesterol, RIAs for thyroid, hormones, endocrine markers, etc.]; Total, Lab-based Immunoassays - Non-
    Infectious; DOA testing - rapid tests; Cancer markers - Rapid tests; Cardiac markers - Rapid tests; Others [Pregnancy, Cancer markers, 
    etc.]; Total, POC - Immunoassays - Non-Infectious; Total – Immunoassays - Non-Infectious)

    BLOOD TESTING AND TYPING

    Table 3-12: Distribution of Blood Centers in Indonesia, by Province

    Non-Standardized Evaluation Protocol

    Table 3-13: Blood Testing and Typing Sales by Category (ABO Grouping, Immunoassays [ELISA and Rapid Tests], NAT), Indonesia, 
    2017-2022

    URINALYSIS

    Table 3-14: List of Major Players in the Indonesian Urinalysis Market

    COAGULATION

    Table 3-15: List of Major Players in the Indonesian Coagulation Market

    Table 3-16: Hemostasis Sales by Category (Lab-based Coagulation Tests, POC Coagulation Tests), Indonesia, 2017-2022

    HISTOLOGY

    Table 3-17: List of Major Players in the Indonesian Histology Market

    Table 3-18: Histology Sales by Category (Traditional Non-Pap Stains, Pap Tests, HPV, Other [includes ISH, IHC, Digital Imaging, CTC, 
    and Flow Cytometry]), Indonesia, 2017-2022

    TOTAL IVD MARKETS IN INDONESIA

    Table 3-19: Total IVD Market in Indonesia by Segment (Microbiology, Hematology, Clinical Chemistry, POC, Immunoassays - Non-
    Infectious Diseases, Blood Testing and Typing, Urinalysis, Coagulation, Histology, Others [includes Molecular Diagnostics (Non-
    Infectious), Supplies, Reagents, IT, Imaging, Automation, etc.]), 2017-2022

    CHAPTER FOUR: IVD COMPANIES, PRIVATE LABS AND DISTRIBUTOR PROFILES

    IVD COMPANY PROFILES

    Abbott Laboratories

    Alere

    Arkray Healthcare

    Beckman Coulter

    Becton, Dickinson and Company (BD)

    bioMerieux

    Bio-Rad

    Cellavision

    Cepheid

    Critical Diagnostics

    DiaSorin S.p.A.

    EKF Diagnostics

    ERBA Diagnostics

    HemoCue AB

    Hologic, Inc.

    Horiba, Ltd.

    Instrumentation Laboratory Company

    Luminex Corporation

    Mindray Medical International Limited

    Nihon Kohden Corporation

    Ortho Clinical Diagnostics

    Qiagen N.V.

    Radiometer Medical ApS

    Randox Laboratories

    Roche Diagnostics

    Siemens Healthineers

    Sysmex Corporation

    Thermo Fisher Scientific

    Tosoh Corporation

    Trinity Biotech

    LEADING PRIVATE LABS IN INDONESIA

    Laboratorium Klinik Utama Bio Medika

    PT Cito Putra Utama

    PT Kimia Farma Diagnostika

    Laboratorium Klinik Pramita

    PT Prodia Widyahusada Tbk

    PROFILES OF SELECTED IVD DISTRIBUTORS IN INDONESIA

    Table 4-1: Profiles of Selected IVD Distributors in Indonesia

    ---------------------------------MEXICO MARKET ANALYSIS


    CHAPTER 1: EXECUTIVE SUMMARY
    INDUSTRY OVERVIEW
    SCOPE AND METHODOLOGY
    MEXICO IVD MARKET SUMMARY
    Figure 1-1: Mexico In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry, Immunoassay Infectious Disease, Immunoassay Other, Microbiology/Molecular, POC Glucose, POC Other, Histology, Other)
    CHAPTER 2: MEXICO OVERVIEW
    POPULATION
    Table 2-1: Total Midyear Population by Broad Age Group: Mexico (million persons), 2010-2050 (0-14, 15-64, 65+, Total Population)
    Figure 2-1: Total Midyear Population by Broad Age Group: Mexico (million persons), 2010-2050 (0-14, 15-64, 65+)
    Figure 2-2: Total Number of Births in Mexico by Year, 1980-2010 and Forecast 2020-2050
    Figure 2-3: Mexico Life Expectancy at Birth in Years, 2010-2050
    Population Urbanization
    ECONOMY AND HEALTH SPENDING
    Figure 2-4: Mexico GDP, GDP (PPP) and Health Spending, 1990-2015
    Figure 2-5: Mexico Distribution of Income or Consumption by Quintile, 1990-2014 (Income share held by highest 20%, Income share held by fourth 20%, Income share held by third 20%, Income share held by second 20%, Income share held by lowest 20%)
    CHAPTER 3: THE HEALTH SYSTEM IN MEXICO
    HEALTH INFRASTRUCTURE
    Figure 3-1: Health Expenditures, Public vs. Private, as a % of Total Health Expenditures, 2015
    Medical Facilities
    Figure 3-2: Distribution of JCI Accredited Facilities by Metropolitan Area (Culiacan, Tijuana, Cancun, Chihuahua, Mexico City)
    Figure 3-3: Distribution of JCI Accredited Facilities by Type (%; Hospital Program, Ambulatory Care)
    Figure 3-4: Distribution of JCI Accredited Facilities by Length of Time from First Accreditation (Withdrawn/Expired, 5+ Years, 2-5 Years, Less Than 2 Years)
    Figure 3-5: Hospital Bed Density per 1,000 Population by Country,2016 Estimates (United States, UnitedKingdom, Singapore, Mexico, Japan, Germany, China, Canada, Brazil, Australia) Physicians and Health Professionals 
    Figure 3-6: Physician Density per 1,000 Population by Country, 2016 Estimates (United States, United 
    Kingdom, Singapore, Mexico, Japan, Germany, China, Canada, Brazil, Australia) 
    Figure 3-7: Nurse/Midwife Density per 1,000 Population by Country, 2016 Estimates (United States,United Kingdom, Singapore, Mexico, Japan, Germany, China, Canada, Brazil, Australia) 
    The Mexican Diagnostic Laboratory Environment 
    Figure 3-8: Laboratories and Collection Sites in Mexico by Type, 2016 (%; Commercial Laboratories,Collection Sites/Patient Service Centers) 
    Figure 3-9: Distribution of Volume, Mexico's Leading Clinical Laboratory Service Providers, 2016 (%) Medical Device Regulation 
    Table 3-1: Market Drivers and Inhibitors for Entering Mexico's Medical Device Market Mexico's Growing Medical Tourism Industry 
    HEALTH INDICATORS
    General Health 
    Disease Profiles in Mexico 
    Table 3-2: Top 5 Cancers Affecting Mexican Population (ranked by total number of cases), 2010-2016 
    Figure 3-10: Medical Conditions/Diseases Prevalence in Mexico (Tuberculosis, Malaria, HIV, Diabetes,Dengue, Cardiovascular Diseases, Cancer)
    CHAPTER 4: IVD MARKETS IN MEXICO 
    MEXICO IVD MARKET SUMMARY 
    Table 4-1: Mexico In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry,Immunoassay Infectious Disease, Immunoassay Other, Microbiology/Molecular, POC Glucose, POC Other, Histology, Other, Total) 
    Figure 4-1: Mexico In Vitro Diagnostic Sales by Market Segment, 2016-2021 (Clinical Chemistry,
    Immunoassay Infectious Disease, Immunoassay Other, Microbiology/Molecular, POC Glucose, POC Other, 
    Histology, Other) 
    Figure 4-2: Mexico In Vitro Diagnostic Sales by Market Segment, 2016 Market Distribution (%) (Clinical Chemistry, Immunoassay Infectious Disease, Immunoassay Other, Microbiology/Molecular, POC GlucosePOC Other, Histology, Other) 
    CLINICAL CHEMISTRY
    Figure 4-3: Mexico - Clinical Chemistry Market, 2016-2021 
    IMMUNOASSAY
    Table 4-2: Mexico - Immunoassay Market Distribution, 2016-2021 (%) (Infectious Disease, Other, Total Immunoassay) 
    Figure 4-4: Mexico - Immunoassay Market Value by Segment, 2016 vs. 2021 (Infectious Disease, Other) 
    MICROBIOLOGY/MOLECULAR
    Table 4-3: Mexico - Microbiology/Molecular Testing Market Distribution, 2016-2021 (%) (Infectious Disease, Other, Total Microbiology/Molecular Testing) 
    Figure 4-5: Mexico Microbiology/Molecular Testing Market Value by Segment, 2016 vs. 2021 (Infectious Disease, Other) 
    POINT-OF-CARE
    Table 4-4: Mexico - POC Market Distribution, 2016-2021 (%) (POC Glucose, POC Other, Total POC)
    Figure 4-6: Mexico POC Market Value by Segment, 2016 vs. 2021 (POC Glucose, POC Other)
    HISTOLOGY
    Figure 4-7: Mexico - Histology Market, 2016-2021
    CHAPTER 5: COMPETITIVE ANALYSIS AND PROFILES
    COMPETITIVE SUMMARY
    Table 5-1: Leading IVD Market Suppliers in Mexico, Market Share Percentage, 2016
    Figure 5-1: Leading IVD Market Suppliers in Mexico, 2016 (%)
    ABBOTT LABORATORIES
    Table 5-2: Abbott Laboratories Company Summary
    Company Overview
    Company Performance
    Product Summary
    BECTON, DICKINSON AND COMPANY
    Table 5-3: Becton, Dickinson and Company Summary
    Company Overview
    Company Performance
    Product Summary
    BIOMÉRIEUX S.A.
    Table 5-4: bioMerieux Summary
    Company Overview
    Company Performance
    Product Summary
    DANAHER
    Table 5-5: Danaher Summary
    Company Overview
    Company Performance
    Product Summary
    DIASORIN S.P.A.
    Table 5-6: DiaSorin S.p.A. Summary
    Company Overview
    Company Performance
    Product Summary
    LIFESCAN, INC
    Table 5-7: LifeScan Summary
    Company Overview
    Company Performance
    Product Summary
    ROCHE (F. HOFFMAN-LA ROCHE, LTD.)
    Table 5-8: Roche Group Summary
    Company Overview
    Company Performance
    Product Summary
    SIEMENS HEALTHINEERS
    Table 5-9: Siemens Healthineers Company Summary
    Company Overview
    Company Performance
    Product Summary
    SYSMEX CORPORATION
    Table 5-10: Sysmex Corporation Summary
    Company Overview
    Company Performance
    Product Summary
    THERMO FISHER SCIENTIFIC
    Table 5-11: Thermo Fisher Summary
    Company Overview
    Company Performance
    Product Summary
    APPENDIX: SOURCES OF INFORMATION


    ---------------------------------IVD IN INDI


    ONE: EXECUTIVE SUMMARY
    Introduction
    Scope and Methodology
    Major Findings of the Report
    India in Context – A Rapidly Developing Economy with Major Demographic
    Challenges
    Demographic Aging
    Disease Drivers
    Infectious Disease Threats
    Indian Economy
    IVD Market in the BRIC Countries
    IVD Market in India
    SWOT Analysis
    Leading Players
    TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD – INDIA IN CONTEXT
    Background
    Population Trends and Disease Demographics
    Obesity
    Disease Trends
    Diabetes
    Cancer
    Allergy and Asthma
    Cardiovascular Disease
    Emerging Viruses and Diseases
    Antimicrobial Drug Resistance
    Clinical Lab Tests
    Types of Tests
    Venues for Test Usage
    Market Segment Opportunities
    Point-of-Care (POC) Testing
    Core Lab Tests
    Molecular Assays
    Hematology
    Coagulation
    Microbiology
    Tests Used in Blood Banking
    Histology and Cytology
    The Future of Indian Economic Growth
    Rising Standards of Living
    Young, English-Speaking Labor Force
    Corruption and Bribery
    Exchange Rate
    BRIC Metrics – Indian IVD Market in Context
    Available Markets – Urban Populations in BRIC Countries
    Paying for Healthcare – Government Expenditures and the Culture of Spending
    Healthcare Capacities in BRIC Nations – A Work in Progress
    IVD Spending
    THREE: INDIA IVD SWOT ANALYSIS
    Introduction
    Strengths – Conditions That Support Market Growth
    Government Support of the Emerging Indian Healthcare Market
    Expanding Medical Education
    Increasing Health Insurance Penetration
    Improving Intellectual Property Protection
    Thriving Biotech Industry
    Contract Research and High Technology
    Returning Scientists
    Growing Hospital Sector
    Expanding Clinical Labs
    Medical Tourism
    Strong IT Sector
    Weaknesses – Factors That Pose Barriers to Market Success and Entry
    Traditional Medicine
    Resource Constraints in Hospitals
    Culture and Business Environment
    Quality and Safety Concerns
    Lack of Medical Device and Diagnostics Regulation
    Lack of IVD R&D
    High Out of Pocket Consumer Expenditures
    Healthcare Pricing
    Opportunities – Rural Healthcare and Technology Partnerships
    Threats – Domestic and Chinese Competition
    Domestic Competition
    Chinese Competition
    FOUR: INDIA IVD MARKET SIZE
    Introduction
    The Market
    Total Indian IVD Market
    Immunoassays
    Clinical Chemistry
    Hematology
    Point of Care/OTC
    Molecular
    Urinalysis
    Other IVD Tests
    FIVE: INDUSTRY AND COMPANY ACTIVITY IN INDIA
    Introduction
    Market Leaders in India
    Indian IVD Players
    International IVD Companies – Recent Activity
    Abbott Laboratories
    Affymetrix, Inc.
    Alere
    Arkray
    Beckman Coulter, Inc./Danaher
    Becton, Dickinson & Co
    Biohit Oy
    bioMérieux, Inc.
    Bio-RAD Laboratories, Inc.
    Daan Gene Co., Ltd.
    Danaher Corp.
    Gen-Probe, Inc.
    Grifols
    Hologic, Inc.
    Horiba Medical
    Instrumentation Laboratory
    Laboratory Corporation of America
    Luminex Corporation
    MedMira
    Mindray Medical International, Ltd.
    Myriad Genetics
    Ortho Clinical Diagnostics
    PerkinElmer
    Promega Corporation
    QIAGEN N.V.
    Quest Diagnostics
    Radiometer A/S
    Roche
    Shanghai Fosun Pharmaceutical Co. Ltd.
    Shanghai Kehua Bio-engineering
    Siemens
    SRL Diagnostics
    Sysmex Corp.
    Thermo Fisher Scientific
    LIST OF EXHIBITS
    ONE: EXECUTIVE SUMMARY
    Exhibit 1-1: Global Map of India
    Table 1-1: BRIC IVD Markets by Country, 2015 - 2020
    Table 1-2: IVD Sales in India by Market Segment (Immunoassays, Clinical
    Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015
    Table 1-3: Indian IVD Growth Rates of Market Segments (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other), 2015-2020,2015-2025 and 2020-2025
    Exhibit 1-2: IVD Market Share in India by Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015, 2020 and 2025
    Exhibit 1-3: IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015, 2020 and 2025
    Exhibit 1-4: Indian Life Expectancy by State, 2014
    TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD – INDIA IN CONTEXT
    Table 2-1: Elderly Support Ratio in India, Other BRIC and Selected Countries(2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World)
    Table 2-2: Selected Worldwide Disease Statistics, 2015 (Respiratory Infections,Malaria, HIV/AIDS, Chlamydia, Gonorrhea, Maternal Conditions, Asthma,Cardiac Disease, Diabetes, Cancer, Syphilis, Tuberculosis, Hepatitis)
    Exhibit 2-1: Diabetes Population by Country, 2015
    Exhibit 2-2: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015
    Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
    Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
    Exhibit 2-3: Countries by Nominal per Capita GDP in 2014
    Exhibit 2-4: Per Capita GDP by Indian Province in 2014
    Exhibit 2-5: Linguistic Map of India
    Table 2-5: Available (Urban) Market Development in BRIC Countries(2003/2015)
    Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries, 2013 (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
    Table 2-7: Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2013) (India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy)
    Table 2-8: Healthcare System Capacities – BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand,Turkey, United Kingdom, United States, Vietnam)
    Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2015(United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India)
    Table 2-10: BRIC IVD Markets by Country, 2015 - 2020 ($ millions)
    THREE: INDIA IVD SWOT ANALYSIS
    Table 3-1: Cost Savings from Medical Tourism for Various Procedures, 2015(Rhinoplasty, Face-Lift, Breast Augmentation, Breast Reduction, Complete Liposuction, Gluteal Augmentation)
    Exhibit 3-1: Ayurvedic Medicine Doshas
    Exhibit 3-2: Ayurvedic Medicine vs. Western Medicine
    Exhibit 3-3: Common Homeopathic Remedies
    Table 3-2: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (% of Total Expenditures) (South Africa,France, United Kingdom, United States, Germany, Thailand, Turkey, Japan,Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico,Indonesia, Vietnam, India, Nigeria)
    Table 3-3: Chinese IVD Companies
    FOUR: INDIA IVD MARKET SIZE
    Exhibit 4-1: Global IVD and Clinical Lab Market, 2015 (India, Russia, Brazil,United Kingdom, Spain, China, Italy, France, Germany, Japan, United States)
    Exhibit 4-2: Global IVD and Clinical Lab Market, 2020 (India, Russia, Brazil,United Kingdom, Spain, China, Italy, France, Germany, Japan, United States)
    Exhibit 4-3: Global IVD and Clinical Lab Market, 2025 (India, Russia, Brazil,United Kingdom, Spain, China, Italy, France, Germany, Japan, United States)
    Table 4-1: Total IVD Sales in India, 2015-2025
    Exhibit 4-4: Total IVD Sales in India, 2015-2025
    Table 4-2: IVD Sales in India by Market Segment (Immunoassays, Clinical
    Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015
    Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015
    Table 4-3: IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2020
    Exhibit 4-6: IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2020
    Table 4-4: IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2025
    Exhibit 4-7: IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2025
    Table 4-5: Immunoassay Sales in India, 2015-2025
    Exhibit 4-8: Immunoassay Sales in India, 2015-2025
    Table 4-6: Clinical Chemistry Sales in India, 2015-2025
    Exhibit 4-9: Clinical Chemistry Sales in India, 2015-2025
    Table 4-7: Hematology Sales in India, 2015-2025
    Exhibit 4-10: Hematology Sales in India, 2015-2025
    Table 4-8: Point of Care/OTC Sales in India, 2015-2025
    Exhibit 4-11: Point of Care/OTC Sales in India, 2015-2025
    Table 4-9: Molecular Test Sales in India, 2015-2025
    Exhibit 4-12: Molecular Test Sales in India, 2015-2025
    Table 4-10: Urinalysis Test Sales in India, 2015-2025
    Exhibit 4-13: Urinalysis Test Sales in India, 2015-2025
    Exhibit 4-14: uChek Urinalysis Test
    Table 4-11: Other IVD Test Sales in India, 2015-2025
    Exhibit 4-15: Other IVD Test Sales in India, 2015-2025
    FIVE: INDUSTRY AND COMPANY ACTIVITY IN INDIA
    Table 5-1: Leading Global IVD Companies in India
    Table 5-2: Selected Domestic IVD Companies in India

    • $7,995
    $11,995
    $15,995

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings